KAT8 (Lysine Acetyltransferase 8), also known as MOF (Males Absent On the First), MYST1, or YBL026W in yeast, is a crucial histone acetyltransferase that primarily acetylates histone H4 at lysine 16 (H4K16ac). This modification is essential for chromatin decompaction and transcriptional activation. KAT8 is highly conserved from yeast to humans and plays fundamental roles in epigenetic regulation, DNA damage response, and cellular homeostasis. Recent research has implicated KAT8 dysregulation in neurodegenerative diseases, making it a protein of interest in Alzheimer's disease (AD) and Parkinson's disease (PD) research.
| Property |
Value |
| Gene Symbol |
KAT8 |
| Gene Name |
Lysine Acetyltransferase 8 |
| Aliases |
MOF, MYST1, YBL026W, KAT8, MOZ |
| Chromosomal Location |
17q11.2 |
| NCBI Gene ID |
84144 |
| OMIM |
609912 |
| UniProt |
Q9H7Z6 |
| Ensembl |
ENSG00000103510 |
KAT8/MOF is a highly conserved histone acetyltransferase belonging to the MYST family (MOZ, YBF2/SAS3, SAS2, TIP60). The enzyme catalyzes the transfer of acetyl groups from acetyl-CoA to lysine residues on histone tails, primarily H4K16, with additional activity at H4K5 and H4K8.
- Primary target: H4K16ac — the hallmark modification that prevents chromatin compaction
- Secondary targets: H4K5, H4K8, H2AK5, H2BK120
- Coenzyme: Acetyl-CoA — linking metabolic state to epigenetic regulation
- Structural features: MYST domain with zinc finger and chromodomain motifs
KAT8 functions within several multi-subunit complexes that direct its substrate specificity and genomic targeting:
- MSL (Male-Specific Lethal) complex: Involved in dosage compensation, primarily X-chromosome upregulation in Drosophila
- NSL (Non-Specific Lethal) complex: Targets euchromatic regions for global transcription activation
- SAGA complex: Participates in transcription elongation and DNA damage response
Beyond histones, KAT8 acetylates:
- p53: Regulates tumor suppressor function and DNA damage response
- TAF4: Transcription factor acetylation
- NF-κB subunits: Modulates inflammatory gene expression
¶ Chromatin Structure and Transcription
H4K16 acetylation by KAT8 is the quintessential "open chromatin" mark:
- Chromatin decompaction: H4K16ac prevents higher-order folding of nucleosome arrays into compact structures
- Transcription factor access: Open chromatin enables RNA polymerase II loading and transcription initiation
- Enhancer activation: H4K16ac at enhancers correlates with transcriptional competence
- DNA damage response: KAT8 is recruited to DNA damage sites and participates in repair
KAT8 maintains cellular homeostasis through:
- Cell cycle regulation: Proper H4K16ac patterns are required for S-phase progression
- Metabolic coupling: Acetyl-CoA levels directly influence KAT8 activity, linking metabolism to epigenetics
- Cellular stress response: KAT8 is recruited to DNA damage sites and participates in repair
¶ Development and Differentiation
Essential for normal development:
- Embryogenesis: Knockout mice show embryonic lethality
- Cell differentiation: KAT8 regulates lineage-specific gene expression programs
- Organogenesis: Critical for brain, heart, and hematopoietic development
KAT8 is widely expressed throughout the central nervous system:
- Neuronal expression: High levels in cortical neurons, hippocampal pyramidal cells, and cerebellar Purkinje cells
- Glial expression: Present in astrocytes and oligodendrocytes
- Subcellular localization: Nuclear, associated with chromatin
KAT8 expression and activity are regulated by:
- Transcription factors: SP1, REST, and neuronal activity-dependent factors
- Post-translational modifications: Phosphorylation, sumoylation
- Cellular signaling: Calcium influx, neurotrophic factors
KAT8 has emerged as a significant player in AD pathogenesis:
- H4K16ac reduction: Studies show decreased H4K16ac in AD brain tissue and cellular models
- Amyloid-beta effects: Aβ treatment reduces KAT8 activity and H4K16ac levels
- Epigenetic therapy potential: KAT8 activators or HDAC inhibitors restore H4K16ac and improve cognitive function in AD mouse models
- Tau pathology connection: KAT8 dysfunction may synergize with tau pathology to drive neurodegeneration
- Gene expression dysregulation: KAT8 alterations contribute to AD-related gene expression changes
Evidence for KAT8 involvement in PD:
- α-Synuclein interaction: KAT8 activity modulated by α-synuclein aggregation
- DNA damage accumulation: KAT8 deficiency exacerbates DNA damage in dopaminergic neurons
- Neuroinflammation: KAT8 regulates inflammatory gene expression in microglia
¶ Intellectual Disability and Rett Syndrome
- KAT8 mutations: Rare de novo mutations associated with neurodevelopmental disorders
- MECP2 interaction: KAT8 works cooperatively with MECP2 in transcriptional regulation
- Synaptic function: KAT8 regulates genes critical for synaptic plasticity
KAT8 dysregulation is observed in multiple cancers:
- Breast cancer: Overexpression associated with poor prognosis
- Lung cancer: Tumor-promoting role through epigenetic reprogramming
- Colorectal cancer: Alters chromatin state to drive oncogenic gene expression
KAT8 represents a potential therapeutic target:
- HDAC inhibitors: Restore H4K16ac levels by inhibiting deacetylases
- Small molecule activators: Direct KAT8 activators under development
- Combination therapy: HDAC inhibitors with standard AD treatments
- H4K16ac as biomarker: Peripheral blood cell H4K16ac levels may reflect brain epigenetic status
- Therapeutic monitoring: Tracking H4K16ac could indicate treatment response
Key methods for studying KAT8:
- ChIP-seq: Genome-wide mapping of KAT8 binding and H4K16ac
- ATAC-seq: Assessing chromatin accessibility
- CRISPR-Cas9: Genetic knockouts and knock-ins
- Biochemical assays: Acetyltransferase activity measurements
- Mass spectrometry: Proteomic analysis of KAT8 complexes
- Cell lines: HEK293, SH-SY5Y neurons, primary neurons
- Animal models: KAT8 conditional knockout mice
- iPSC models: Neurons derived from patient iPSCs
KAT8/MOF is a critical histone H4K16 acetyltransferase essential for chromatin decompaction and transcription regulation. Beyond its fundamental roles in epigenetics, KAT8 has emerged as a significant player in neurodegenerative diseases, particularly Alzheimer's disease, where reduced H4K16ac contributes to transcriptional dysfunction and cognitive decline. The enzyme represents a promising therapeutic target for epigenetic-based interventions in neurodegeneration.